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The polyol pathway is a two-step metabolic pathway in which glucose is reduced to sorbitol, which is then converted to fructose.
It is one of the most attractive candidate mechanisms to explain, at least in part, the cellular toxicity of diabetic hyperglycemia
because (i) it becomes active when intracellular glucose concentrations are elevated, (ii) the two enzymes are present in human
tissues and organs that are sites of diabetic complications, and (iii) the products of the pathway and the altered balance of cofactors
generate the types of cellular stress that occur at the sites of diabetic complications. Inhibition (or ablation) of aldose reductase,
the ﬁrst and rate-limiting enzyme in the pathway, reproducibly prevents diabetic retinopathy in diabetic rodent models, but the
results of a major clinical trial have been disappointing. Since then, it has become evident that truly informative indicators of
polyol pathway activity and/or inhibition are elusive, but are likely to be other than sorbitol levels if meant to predict accurately
tissue consequences. The spectrum of abnormalities known to occur in human diabetic retinopathy has enlarged to include glial
and neuronal abnormalities, which in experimental animals are mediated by the polyol pathway. The endothelial cells of human
retinal vessels have been noted to have aldose reductase. Speciﬁc polymorphisms in the promoter region of the aldose reductase
gene have been found associated with susceptibility or progression of diabetic retinopathy. This new knowledge has rekindled
interest in a possible role of the polyol pathway in diabetic retinopathy and in methodological investigation that may prepare new
clinical trials. Only new drugs that inhibit aldose reductase with higher eﬃcacy and safety than older drugs will make possible
to learn if the resilience of the polyol pathway means that it has a role in human diabetic retinopathy that should not have gone
undiscovered.
Copyright © 2007 Mara Lorenzi.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The question of whether the minor pathway of glucose
metabolism,calledthepolyolpathway,isanimportantplayer
in retinopathy and other complications of human diabetes
has been asked for over three decades [1], and the answer is
not yet in. Such state of things begets two questions: why do
we not have an answer yet? and perhaps more pointedly, why
is the question still alive?
Theanswertotheﬁrstquestionbeginsasdirectandprac-
tical, but becomes interlocutory. We have not had probes to
address rigorously the question of whether the polyol path-
way has a pathogenic role in human diabetic retinopathy. In
practical terms, we have not had available drugs with a high
therapeutic index in humans, that is, eﬀective and well tol-
erated at the same time, so as to make possible their usage
at doses documented to inhibit the pathway fully and pre-
dictablyinthetissuesofinterest.Butdoweknowwhichisthe
gold standard by which to measure “inhibition of the polyol
pathway”? We are becoming aware that such knowledge is
pivotal, and not easy to acquire. The answer to why we are
still courting and querying the polyol pathway has to do with
both the current treatment of diabetes and the polyol path-
way itself. Intensive glycemic control is clearly eﬀective in re-
ducing the incidence and progression of diabetic retinopathy
[2,3],butwiththemeansavailabletodayeventhebesteﬀorts
do not achieve normal glucose homeostasis, and retinopathy
and other complications continue to develop and progress
to clinically important stages also among well-controlled pa-
tients [2–4] .W ea r en o ty e ta b l et oo ﬀer adjunct treatments
that can preempt the damaging eﬀects of the residual hyper-
glycemia. The polyol pathway is by all criteria an enormously
attractive target for adjunct treatment. The polyol pathway is
also enormously resilient, and just when investigators try to
put it aside, it scores new points and returns to the fore.
Over three decades, much has been written on the polyol
pathway and the complications of diabetes, and much has
been captured in informative reviews [5, 6]. My goal in this
writing is to extract from the existing body of knowledge
what justiﬁes a continuous interest in the pathway from the2 Experimental Diabetes Research
standpoint of human diabetic retinopathy, and to highlight
actions needed to give the pathway a role or a dismissal.
2. THE POLYOL PATHWAY IS A PLAUSIBLE
BIOCHEMICAL MECHANISM FOR
DIABETIC RETINOPATHY
T h ep o l y o lp a t h w a yo fg l u c o s em e t a b o l i s mb e c o m e sa c t i v e
when intracellular glucose levels are elevated [1, 5]. Aldose
reductase (AR), the ﬁrst and rate-limiting enzyme in the
pathway, reduces glucose to sorbitol using NADPH as a co-
factor; sorbitol is then metabolized to fructose by sorbitol
dehydrogenase that uses NAD+ as a cofactor. The eﬀects are
several.Sorbitolisanalcohol,polyhydroxylated,andstrongly
hydrophilic, and therefore does not diﬀuse readily through
cell membranes and accumulates intracellularly with pos-
sible osmotic consequences [1]. (Production of intracellu-
lar osmolytes to counterbalance extracellular hypertonicity
is a likely physiological role of AR in the kidney medulla
[7].) The fructose produced by the polyol pathway can be-
come phosphorylated to fructose-3-phosphate [8, 9], which
is broken down to 3-deoxyglucosone; both compounds are
powerful glycosylating agents that enter in the formation of
advanced glycation end products (AGEs) [8]. The usage of
NADPH by AR may result in less cofactor available for glu-
tathione reductase, which is critical for the maintenance of
the intracellular pool of reduced glutathione (GSH). This
would lessen the capability of cells to respond to oxida-
tive stress [10]. Compensatory increased activity of the glu-
cose monophosphate shunt, the principal supplier of cellu-
lar NADPH, may occur [10] .T h eu s a g eo fN A Db ys o r b i t o l
dehydrogenase leads to an increased ratio of NADH/NAD+,
which has been termed “pseudohypoxia” and linked to a
multitude of metabolic and signaling changes known to al-
ter cell function [11]. It has been proposed that the excess
NADH may become a substrate for NADH oxidase, and this
wouldbeamechanismforgenerationofintracellularoxidant
species [12]. Thus, activation of the polyol pathway, by al-
tering intracellular tonicity, generating AGEs precursors, and
exposing cells to oxidative stress perhaps through decreased
antioxidant defenses and generation of oxidant species, can
initiate and multiply several mechanisms of cellular damage.
Retinal ganglion cells, M¨ uller glia, and vascular pericytes
and endothelial cells are endowed with aldose reductase in
all species studied, including humans (reviewed in [13]).
Hence, these cell types are exposed to polyol pathway ac-
tivation in diabetes. These are also the cells that manifest
the best-known changes or damage in diabetes [14]. The
biochemical consequences of polyol pathway activation have
been studied in the whole retina of diabetic animals. The
best-documented are the accumulation of sorbitol and fruc-
tose [15, 16], and the generation or enhancement of oxida-
tive stress. The retina of experimentally diabetic rats shows
increased lipid peroxidation products [16], increased ni-
trotyrosine [17], and depletion of antioxidant enzymes [16].
These abnormalities are prevented by drugs that inhibit AR
[15–17]. Insofar as indices of polyol pathway-induced oxida-
tive stressare measurablein preparations ofthe wholeretina,
the abnormalities are likely to occur in most cell types or at
least in cells that are highly represented in the whole retina.
M¨ uller glial cells are candidates because they are large cells
presentinhighnumberintheretina[18].Wecannotexclude
that other mechanisms of polyol pathway-induced damage
may be operative in selected types of retinal cells. For exam-
ple, osmotic stress seemingly cannot be invoked from data
in the whole retina because retinal levels of sorbitol increase
in diabetic rats only 3–8 fold above control [15, 16], and are
far from the concentrations that could induce osmotic stress
[1]. However, a cell type that had an especially high ratio
of AR to sorbitol dehydrogenase could accumulate sorbitol
with intracellular consequences, and yet the amount would
be diluted substantially in measurements taken in the whole
retina. Investigation that compares and contrasts the kinetics
and consequences of polyol pathway activation in the rele-
vant retinal cell types—neurons, M¨ uller glia, pericytes, and
endothelial cells—might therefore generate important new
insights. At this time, the information from the biochemi-
cal measurements and the dose-response studies with ARIs
point to oxidative stress as the strongest candidate mecha-
nism for polyol pathway-dependent cellular damage in the
diabetic retina.
3. THE POLYOL PATHWAY IS A CONTRIBUTOR TO
EXPERIMENTAL DIABETIC RETINOPATHY
Twowavesofstudiesaddressedtheroleofthepolyolpathway
in experimental diabetic retinopathy. A ﬁrst wave of studies
centered on the galactosemic model. In the early 80’s, En-
german and Kern described the diabetic-like retinopathy of
dogs fed a diet rich in galactose [19], and Robison et al. re-
ported that the basement membrane thickening seen in the
retinal capillaries of rats fed a diet rich in galactose was pre-
vented by an AR inhibitor (ARI) [20]. The observation that
galactosemia, that is, the isolated elevation of a hexose in
blood without other hormonal or metabolic abnormalities
[19],couldmimic mostfeaturesoftheretinalmicroangiopa-
thy caused by diabetes is, to date, the most speciﬁc indict-
ment of the role of hyperglycemia in causing retinopathy
in diabetes. (The design of the Diabetes Control and Com-
plications Trial [DCCT], where intensive insulin treatment
ameliorated the diabetic state comprehensively, cannot iso-
late precisely the beneﬁts of correcting hyperglycemia, and
thus the role of hyperglycemia in the complications.) The
galactosemic model was highly relevant to the polyol path-
way because the set of enzymes necessary to permit the entry
ofdietarygalactoseintotheglycolyticpathwayispresentonly
in the liver [21]. In congenital disorders where enzymes of
galactose metabolism are defective, blood galactose levels in-
crease and many peripheral tissues accumulate two metabo-
lites, galactose-1-phosphate, and galactitol [21]. Galactitol is
produced from galactose via the action of AR; and the AR
from all species studied—human, dog, and rat—displays a
lower Km for galactose than for glucose [22]. An ARI, given
at a dose of 65mg/Kg/day prevented the diabetic-like retinal
vascular histopathology developed by rats fed a 50% galac-
tose diet [23]. However, the full complement of retinal mi-
croangiopathy developed by dogs fed a 30% galactose diet
was only delayed [24]o rn o tp r e v e n t e da ta l l[ 25] by theMara Lorenzi 3
ARI sorbinil. The dose of sorbinil used in the galactose-fed
dogs (60mg/Kg/day on average) and devised to inhibit ac-
cumulation of galactitol in erythrocytes was not diﬀerent
from the dose used in the galactose-fed rats. One group of
investigators noted, however, that sorbinil was metabolized
more rapidly in dogs than in rats, yielding unexpectedly
short plasma half-life [24]. The same group also examined
retinal changes in the galactose-fed dog model treated with
two doses of a sorbinil analog, and found evidence for dose-
dependency of the beneﬁcial eﬀects of ARI treatment [26].
In one of the above studies, experimentally diabetic dogs
were studied alongside galactose-fed dogs [25]. To diabetic
dogs, sorbinil was administered in a lesser dose (20mg/Kg/
day) than to galactosemic dogs, targeting inhibition of dia-
betes-induced sorbitol accumulation in erythrocytes. The
dose yielded 90% sorbitol inhibition in erythrocytes as well
as retina. However, sorbinil did not prevent the development
of retinal microangiopathy in the diabetic dogs [25]. Shortly
before, the ﬁnal results of the sorbinil retinopathy trial had
become available. The trial had tested sorbinil at a dose of
250mg/day (the equivalent of 3.5mg/Kg/day in a 70Kg in-
dividual), administered for 3 years to patients with type 1
diabetes with absent or very mild retinopathy. The data indi-
cated that sorbinil did not have a clinically important eﬀect
on the course of human diabetic retinopathy [27]. Interpre-
tativecaveatsapplytothesenegativeresults,asdiscussedlater
in this writing. Nonetheless, at the time the results under-
standably dampened the enthusiasm in pursuing the polyol
pathway as a major player and target in diabetic retinopathy.
However, when new features of diabetic retinopathy be-
came known in the late 90’s, the polyol pathway commanded
a second wave of investigations, showing its resilience. We
developed an interest in the polyol pathway because it was
the rational ﬁrst choice for a new mechanistic question. We
wishedtounderstandthemechanismforthereactivecharac-
teristicsofM¨ ullerglialcells[28,29]andapoptosisofneurons
(mostly ganglion cells) [30] occurring early in both human
and experimental diabetic retinopathy; and M¨ uller and gan-
glion cells are the retinal cell types most consistently found
to contain aldose reductase in humans, rats, and dogs [31–
34]. In view of the fact that sorbinil had failed to prevent
the lesions of retinopathy in diabetic dogs when used at a
dose of 20mg/Kg/day [25], we selected the larger dose used
inthegalactosemicmodels.Weobservedthat,intheretinaof
rats with 2.5 months of diabetes, neurons undergoing apop-
tosis indeed contained aldose reductase, and that sorbinil
65mg/Kg/day prevented neuronal apoptosis, the prominent
increase in glial ﬁbrillary acidic protein (GFAP) in M¨ uller
cells indicating a reactive state, and changes in astrocytes
[15].
The question arose whether in the diabetic rat also the
vascular abnormalities of retinopathy receive a contribution
from the polyol pathway. ARIs had been noted to prevent
hemodynamic changes and vascular permeability changes in
rats with 6 weeks of diabetes [35] and retinal capillary base-
ment membrane thickening in rats with 6 months of dia-
betes [36]. Surprisingly, there were however no published
studies addressing, in diabetic rats, the eﬀect of aldose re-
ductase inhibition on the ultimate manifestations of retinal
microangiopathy in diabetes, apoptosis of pericytes and en-
dothelial cells, and development of acellular capillaries. We
had shown that microvascular cell apoptosis precedes [37]
and predicts [38] the development of acellular capillaries,
which is in turn a key event in diabetic retinopathy [39, 40]
because it heralds retinal ischemia and, in humans, transi-
tion to sight-threatening proliferative retinopathy. We thus
view the development of acellular capillaries as the required
read-out for any modeling, pathogenetic construct, or inter-
vention related to the microangiopathy of diabetic retinopa-
thy. We went on to perform the studies addressing the role of
the polyol pathway, and we targeted vascular abnormalities
that we had documented to occur also in the human diabetic
retina[37,41].Theretinalvesselsofdiabeticratstreatedwith
sorbinil for the 9-month duration of diabetes showed pre-
ventionof(i)earlycomplementactivation,(ii)decreasedlev-
els of complement inhibitors, (iii) microvascular cell apop-
tosis, and (iv) acellular capillaries [13]. Also other investiga-
tors had reported sparing of pericytes by treatment with an
ARI other than sorbinil in rats with 15 months of diabetes
[42]. (In this particular study the pericyte counts were per-
formed in retinal sections, specimens that are suboptimal for
the purpose.) Insofar as the pericytes and endothelial cells of
ratretinalvesselscontainAR[13],itisplausiblethattheARIs
prevented the microangiopathy by inhibiting polyol pathway
directly in vascular cells.
The diabetic mouse has contributed information that
supports the role of the polyol pathway in diabetic retinopa-
thy, but has generated an important question as yet unan-
swered. We compared and contrasted the mouse to the rat
because of the known diﬀerences in polyol pathway activa-
tion between these species. The mouse is known to have, in
the lens, one-tenth of the aldose reductase activity present in
the rat lens [43], and its extreme resistance to cataract un-
der conditions of hyperglycemia [43] and galactosemia [44]
can be overcome only by introduction of a human aldose re-
ductase transgene [44, 45]. We reasoned that the mouse may
have low aldose reductase activity also in the retina. In fact,
C57BL/6J mice, rendered diabetic with streptozotocin and
exhibiting hyperglycemia as severe as diabetic rats, did not
accumulate sorbitol or fructose in the retina [15]. Obrosova
etal.madesimilarobservations,andreported additional and
important biochemical diﬀerences between the retinas of di-
abetic mice and diabetic rats [46]. The diabetic mice did not
show apoptosis of ganglion cells or reactivity of M¨ uller glial
cells, and this was consistent with the evidence in diabetic
rats that polyol pathway activation is the inducer of the neu-
roglial abnormalities. A diﬀerent group of investigators con-
ﬁrmed the absence of neuronal apoptosis and M¨ uller cell re-
activity in C57BL/6J mice studied up to one year-duration
of streptozotocin-diabetes [47]. Two groups reported instead
loss of retinal neurons in diabetic mice, one group in the
streptozotocin model [48] and the other in the Ins2AKITA
mouse maintained on the C57BL/6J background [49]. These
reports did not present counts of apoptotic cells; the conclu-
sions on neuronal death were based on assays for activated
caspase 3 and/or morphometry of retinal layers. Nor did the
studies investigate retinal polyol pathway activity. However,
the Ins2AKITA mouse was speciﬁcally reported not to show4 Experimental Diabetes Research
M¨ uller cell reactivity [49], in agreement with the ﬁndings in
the streptozotocin diabetic mouse [15, 47]. Recent observa-
tionsindb/dbmice,whichareamodelfortype2diabetes,in-
dicate that very long duration of diabetes (15 months) leads
to increased expression of retinal AR, M¨ uller cell reactivity,
neural cell apoptosis, and vascular changes; and that these
abnormalities do not appear in db/db mice rendered genet-
ically AR-deﬁcient [50]. Thus, in diabetic mice, retinal neu-
roglial abnormalities are not found as consistently as in di-
abetic rats. When neuroglial abnormalities are undetectable,
polyol pathway activity is likewise undetectable. When neu-
roglial abnormalities are present, polyol pathway activity ap-
pears to be the inciting cause.
The question generated by the diabetic mouse and as
yet unanswered is the relationship of acellular capillaries
to the polyol pathway in this model. The streptozotocin-
diabetic C57BL/6J mouse model develops a progressively
greater number of acellular capillaries with increasing dura-
tionofdiabetes,andtheaccelerationovercontrolbeginsafter
6monthsofdiabetes[47],whenneitherretinalaccumulation
of polyols nor neuroglial abnormalities can be demonstrated
[15, 47]. Does this indicate that in the diabetic mouse reti-
nal vascular cells activate the polyol pathway and are dam-
aged by the consequences, when neural and glial cells do not,
or not as yet? Because vascular cells represent only a minor
contribution to total retinal cellularity, their accumulation of
polyols would go unnoticed in preparations of whole retina.
Unfortunately, the studies in the AR-null db/db mice could
not answer the question, because the development of acellu-
lar capillaries was not addressed speciﬁcally. (In that model,
vessels were actually reported to be present in larger num-
ber than in nondiabetic mice [50]. An important interpreta-
tive caveat is that the vessels were counted as dots or tubes
staining for IgG on retinal sections; and the number of such
images can be inﬂuenced by several confounders, such as the
plane and thickness of sections, as well as vessel tortuosity
and the state of vessel perfusion.)
To summarize the observations in animal models, there
is weighty evidence for the concept that polyol pathway ac-
tivation is a suﬃcient mechanism for the retinal abnormali-
ties induced by diabetes in the rat. One missing piece of ev-
idence precludes a similar comprehensive conclusion in the
diabeticmouse.Theresultsfromthediabeticdogstudiesand
the sorbinil trial do not support the importance of the polyol
pathway in the development of diabetic retinopathy in the
dog model or in humans. But these latter experiments are
the older, and it is becoming apparent that, if designed today,
they would be designed diﬀerently. We examine the issues in
the following sections.
4. DO WE KNOW HOW TO SILENCE THE POLYOL
PATHWAY WHEN THE GOAL IS PREVENTION OF
TISSUE DAMAGE?
T h ep o l y o lp a t h w a yi s ,a tﬁ r s tg l a n c e ,ad r e a mt a r g e tw h e n
aiming to develop drugs for prevention of the complications
of diabetes. The rate-limiting enzyme of the pathway, AR,
acts on the glucose molecule, and therefore at the most up-
stream possible site in the cascade of glucose toxicity. AR is
encoded by one gene [5, 51], has a known structure and ki-
netic properties [52], and its activity is inhibitable by mul-
tiple classes of small molecule compounds [53]. Complete
AR deﬁciency produces only a mild nephrogenic diabetes in-
sipidus [54]. On this basis, AR inhibition appears rational,
feasible,andbenign;andifwecouldjustaddtothetoolsare-
liable indicator of AR inhibition permitting us to target and
monitor in tissues the therapeutic eﬀects of ARIs, we could
readily implement rigorous preclinical studies and clinical
trials.
However, the “reliable indicator of AR inhibition” is
turning out to be an elusive target, and the reason is that we
do not know for certain how polyol pathway activity causes
tissue damage. What we know is that when ARIs have been
dosedtopreventsorbitolaccumulation,asinthestudieswith
diabetic dogs or the sorbinil trial (where sorbitol was mon-
itored in red blood cells, and not even normalized there),
very little tissue beneﬁt has ensued. When ARIs have been
used in larger doses targeted to prevent the accumulation of
fructose rather than sorbitol, they have been more success-
ful. The concordant dose-dependency for eﬀects on fructose
and tissue abnormalities has been demonstrated directly in
the nerve [55], and was also seen clearly in the retina. When
we tested ARIs on diabetic retinopathy in the rat, we used a
65mg/kg/day sorbinil dose [13, 15] that was shown in pre-
liminary experiments to inhibit both sorbitol and fructose
formation. The greater relevance of fructose than sorbitol as
measure of polyol pathway activity is easily understandable
when thinking that sorbitol accumulation may be minuscule
under conditions in which AR is very active if also sorbitol
dehydrogenaseisveryactive.Undersuchconditions,sorbitol
levels may never increase and yet the pathway will have pro-
cessed a large amount of glucose, and the ﬂux of glucose will
haveusedNADPHandgeneratedNADHandfructose.These
may ultimately be the more relevant abnormalities for cells
and tissues. Oates et al. are currently showing that in diabetic
ratnervetheratioofoxidizedglutathione(GSSG)toreduced
glutathione (GSH) increases, indicating oxidative stress; and
thatnormalizationoftheratiorequiresanevenlargerdoseof
ARI than the normalization of fructose, at least in acute ex-
periments [56]. The implication of these studies is very im-
portant: if we must limit the oxidative consequences of the
polyol pathway in order to limit its cellular toxicity, we may
need to inhibit AR much more drastically, at least to the de-
greeachievedinrecentratstudies[13,15–17],andsuchinhi-
bition required doses of ARIs twenty times larger than those
used in the sorbinil trial.
A noteworthy issue with ARIs is that they can inhibit
also aldehyde reductase, another enzyme in the aldo-keto
reductase superfamily that plays a role in the detoxiﬁcation
of reactive aldehydes [22, 57, 58]. All ARIs inhibit AR more
than aldehyde reductase, but some ARIs such as sorbinil do
not have a high degree of selectivity for AR versus alde-
hyde reductase [22, 53, 57]. This generates the question of
whether some inhibition of aldehyde reductase contributes
tothebeneﬁcialeﬀectsofARIs,especiallyatthehigherdoses;
or, conversely, contributes unwanted side eﬀects. We recently
had the opportunity to test an ARI from an entirely new
structural class, a sulfonylpyridazone characterized as one ofMara Lorenzi 5
the most potent and selective ARIs yet described. In particu-
lar, the IC50 of ARI-809 (compound 19m in [53]) for alde-
hyde reductase is 930nM as compared to 1nM for AR [53].
Suchselectivitypermittedustotargetcriticallytheroleofthe
polyol pathway in the early stages of the development of ex-
perimentaldiabeticretinopathy.ARI-809administeredtodi-
abetic rats at doses documented to inhibit both sorbitol and
fructose accumulation in the retina, improved survival, in-
hibited cataract development, and protected the retina from
all early neuronal, glial, and vascular abnormalities known
to also occur in human diabetes [59]. On this basis, it can be
statedthataldosereductaseisitselfthekeyrelaythatconverts
hyperglycemia into glucose toxicity for speciﬁc cell types in
the retina. Whether ARI-809 or other highly speciﬁc ARIs
will also help address the problem of toleration and side ef-
fects will need to be addressed in humans.
If further experiments conﬁrm that only large ARI doses
can block the polyol pathway to the extent required to pre-
vent tissue damage, we are clearly poorly equipped to bring
the concept to test in humans. The two chemical classes of
ARIs that have been mostly tested in phase III trials, the car-
boxylicacidinhibitors(e.g.,zopolrestat)andthespirohydan-
toin inhibitors (e.g., sorbinil), have a suboptimal therapeu-
tic index. Both classes have shown side eﬀects: liver and/or
renal toxicity in the former, and potentially serious hyper-
sensitivity reactions in the latter [27]. The diﬀerent type of
side eﬀects suggests that they are not consequences of AR
inhibition, but rather of other properties of the individual
drugs. Nonetheless, the side eﬀects would preclude any es-
calation of the doses tested to date. There are new ARIs
of the spiroimide/hydantoin class that show greater potency
than sorbinil, and have achieved in diabetic patients a ro-
bust inhibition of the polyol pathway in sural nerves [60], as
well as improvement in signs and symptoms of sensorimotor
polyneuropathy at well-tolerated doses [61–63]. The results
of larger trials with these drugs are expected soon.
5. IS THE POLYOL PATHWAY IMPORTANT IN
HUMAN DIABETIC RETINOPATHY? AND WHY
SHOULD WE CARE TO KNOW?
The results of the sorbinil retinopathy trial could have been a
false negative or a true negative. A false negative could have
occurred for at least two reasons. The ﬁrst is that the dose of
sorbinil may have been insuﬃcient to achieve and sustain in-
hibitionofretinalpolyolpathway;wefoundthatmuchlarger
doses—not usable in humans—were needed to achieve pre-
vention of retinal polyol pathway activation in the diabetic
rat [13, 15]. When the intent is to test a pathogenic mech-
anism for disease, there is a stringent requirement for docu-
mentationthatthechoseninterventioninhibitsorattenuates
the target mechanism at the sites of interest. The DCCT and
UnitedKingdomProspectiveDiabetesStudywhichsetoutto
test the role of metabolic control in the complications of di-
abetes implemented laborious strategies to verify before the
trial,anddocumentextensivelythroughoutthetrial,thattwo
levels of glycemic control could be achieved and maintained,
and that they were suﬃciently apart in a suﬃcient number
of study participants to permit testing the hypothesis. Un-
certainty about whether a drug or intervention is delivered
in suﬃcient dose to achieve eﬀects at target tissue is a recur-
rent issue in clinical trials. It continues to be one of the most
commonly proposed mechanisms to explain discrepancies
betweenencouragingpreclinicalstudiesandinconclusivetri-
als. Just recently, it was discussed with regard to the beneﬁts
of insulin-like growth factor-1 in motor neuron diseases [64]
and exogenous surfactant replacement in the acute respira-
torydistresssyndrome[65].Thesecondreasonforwhichthe
sorbinil trial could have yielded false negative results is that
it was an intervention trial, where approximately half of the
study population had clinical evidence of retinopathy, albeit
mild [27]. Interventions do not work as well as prevention
in diabetic retinopathy [2]. This is likely to be especially true
for interventions such as ARIs that target early events in the
cascade that leads to the demise of retinal vascular cells.
It remains possible that the results of the sorbinil trial
were a true negative, and it appears wise to investigate
how solid is the rationale for advocating new rigorous tri-
als. Information gathered by studying post-mortem eyes is
consistent with activity of the polyol pathway in human
diabetes. Retinas from diabetic patients with retinopathy
showmoreabundantARimmunoreactivityinganglioncells,
nerve ﬁbers, and M¨ uller cells than retinas from nondiabetic
individuals [66]. In our experiments, human retinas from
nondiabetic eye donors exposed to high glucose levels in or-
gan culture accumulate sorbitol to the same extent as sim-
ilarly incubated retinas of nondiabetic rats, as well as reti-
nas dissected from diabetic rats [13]. The comparable bio-
chemical outcome of AR activity in the human and rat reti-
nas underscores that human AR is readily responsive to hy-
perglycemia. The human enzyme is in fact widely used as a
transgene to make the mouse susceptible to diabetic compli-
cations, from cataract [45] to atherosclerosis [67]. It is thus
apparent that cells in the human retina—including vascu-
lar endothelial cells and pericytes [13]—can have an active
polyol pathway in the presence of hyperglycemia.
An additional type of new information that justiﬁes re-
visiting the role of the polyol pathway in human diabetic
retinopathy is the ﬁnding that several polymorphisms in the
promoter region of the AR gene are associated with suscep-
tibility to, or more rapid progression of, diabetic retinopathy
(reviewed in [51]). Of particular interest has been the Z−2
allele of the (AC)n dinucleotide repeat sequence located 2.1
kb upstream of the AR transcription start site [68]. The Z−2
allele is in linkage disequilibrium with another polymor-
phism in the AR promoter that also increases susceptibility
to retinopathy [69]; and appears to be associated with higher
levels of AR mRNA [70]. Of much interest, the association of
the Z−2 allele with increased AR expression was found only
in diabetic patients, not among nondiabetic individuals [70],
suggesting an interaction with diabetes/hyperglycemia. Al-
though the best-known type of interaction of hyperglycemia
with AR is to provide substrate for activity of the enzyme
(which has a high Km for glucose), there are reports indi-
cating also an eﬀect of hyperglycemia on AR gene expression
[71,72].Itcanbeexpectedthatsucheﬀectwouldincreasethe6 Experimental Diabetes Research
magnitude of polyol pathway activation and its tissue conse-
quences.
However, the ultimate question is not whether further
investigation of the polyol pathway in diabetic retinopathy
is justiﬁed, but rather whether it is needed. After all, the
polyol pathway is not the only candidate mechanism for
diabetic retinopathy on which to base the development of
adjunct treatments. In experimentally diabetic animals sev-
eral interventions targeting pathogenic mechanisms other
than the polyol pathway have proven to be capable of in-
hibiting the development of retinal acellular capillaries—
aminoguanidine [38, 73] and pyridoxamine [74] given to in-
hibit AGE formation, benfotiamine [75]g i v e nt od i v e r tg l y -
colytic intermediates from pathways of hyperglycemic dam-
age, the poly(ADP-ribose) polymerase (PARP) inhibitor PJ-
34 [76] given to counteract the potentially proinﬂammatory
action of PARP, and aspirin [77, 78] given at doses that have
antiplatelet and anti-inﬂammatory eﬀects. The ﬁrst three
compounds targetupstreamconsequencesofhyperglycemia.
Even if some AGEs precursors are generated through polyol
pathway activation [8, 9, 11], it is actually encouraging that
drugs that inhibit AGE formation without having any eﬀect
on AR such as aminoguanidine [38] can prevent the devel-
opment of acellular capillaries. PARP inhibitors and aspirin
are likely to work on downstream events. The fact that re-
moving one upstream or downstream contribution to the
development of acellular capillaries lessens or delays consid-
erably their development indicates that there is interaction
and reinforcement among the causative events triggered by
diabetes. If such concept applies also to human retinopathy,
it would justify the development of multiple adjunct drugs
of diﬀerent classes, thus able to accommodate issues of sen-
sitivity and tolerance by individual patients, and usable in
combinations that may maximize eﬃcacy and safety.
Recent ﬁndings, however, indicate that some conse-
quences of the polyol pathway may be preventable only by
ARIs. We contrasted the eﬀects of aspirin, clopidogrel (a se-
lectiveantiplateletagent),andsorbinil onthecomprehensive
picture of diabetic retinopathy, and found that both aspirin
and sorbinil succeeded in preventing the acellular capillaries,
but only sorbinil prevented the reactive phenotype of M¨ uller
cells [78]. Weobtained identical resultsusing the structurally
novel and highly selective ARI-809 [59]. To our knowledge,
ARIs are the only type of drugs shown to date to prevent the
M¨ uller cell reactivity that occurs in the diabetic rat retina,
and that is also characteristic of human diabetic retinopathy
[28]. We do not know yet whether and where the M¨ uller cell
reactivity is important in the process of diabetic retinopathy,
but the arguments we see in support of this possibility have
prompted us to begin experimental testing. M¨ uller cells have
essential roles in the whole retina, from structural support
to neurotransmitter metabolism [18], and uniquely special-
ized roles in the inner retina—formation and maintenance
of the blood-retinal barrier, and dehydration of the intersti-
tium by pumping water into the capillaries [79, 80]. In pri-
mates, the M¨ uller cell density is over 5 times greater in the
parafovealthaninperipheralregionsoftheretina[18].These
characteristics make dysfunctional M¨ uller cells relevant to
the development of macular edema, a complication of dia-
betic retinopathy that cannot be studied in the usual animal
models, because rodents do not have a macula. In human di-
abetes, macular edema is characterized by the accumulation
of extracellular ﬂuid in Henle’s layer and the inner nuclear
layer of the retina, and the clinically important accumulation
is thought to require not only increased inﬂux of water from
the abnormally permeable capillaries, but also a defect in
the reabsorptive mechanism. The M¨ uller cells are such reab-
sorbing mechanism for the inner retina [80]. Diabetic mac-
ular edema is strongly associated with poor glycemic control
[reviewed in [81]]. Poor glycemic control means for M¨ uller
cells high intracellular glucose because they have mostly the
insulin-independent GLUT-1 glucose transporters [82], and
high levels of polyol pathway activity on account of the espe-
cially abundant AR levels. This combination may expose the
cells to all consequences of the pathway including oxidative
and osmotic stress.
On the basis of the biochemical data obtained in the
whole retina [13, 15, 16, 46], we expect that M¨ uller cells ex-
perience oxidative stress from activation of the polyol path-
way, and that this triggers the reactive phenotype. However,
if M¨ uller cells were to experience in human diabetes also
osmotic consequences of the polyol pathway, there would
be two novel implications for human diabetic retinopathy.
The ﬁrst would be the identiﬁcation of a discrete biochem-
ical mechanism for the cystoid features of macular edema
in diabetes, because swelling of M¨ uller cells themselves is
at the basis of cystoid edema [80]. The second implication
would be that no other drugs but ARIs could be expected
to correct this particular mechanism for M¨ uller cell abnor-
malities. We know that diabetes induces a large number of
changes in gene expression in M¨ uller cells indicating both a
reactive phenotype and altered functions [83], and the na-
ture of the changes suggests multiple inducing mechanisms.
It is thus likely that prevention of the spectrum of M¨ uller cell
abnormality does require the high doses of ARIs we tested
[15, 59, 78], but it is possible that osmotic consequences of
polyol pathway activation may be approachable with lesser
doses. Then, ARIs would have three diﬀerent indications re-
latedtodiabeticretinopathy—aﬁrstanduniqueonedirected
at the acute relief of macular edema, a second one directed at
thepreventionofbothmacularedemaandmicroangiopathy,
and a third one directed at the prevention of macular edema
in the context of a drug combination where the other drug
targets the microangiopathy. In view of the diﬀerent dura-
tion of treatment required by the diﬀerent indications and
the diﬀerent speciﬁc targets, the three indications could be
served by ARIs that diﬀer in potency as well as therapeutic
index. New experiments will now address these speculative
possibilities.
6. CONCLUSIONS
T h el a t e s tw a v eo fs t u d i e so nt h ep o l y o lp a t h w a yh a sg i v e nu s
a more complete picture of what the pathway can do in the
h u m a nr e t i n a ,a n dh o w .T h ep o l y o lp a t h w a yc a nb ea c t i v e
in the human retina; it can be active in endothelial cells and
not just in pericytes; it can be the mechanism for the changes
we see in the M¨ uller cells of human diabetic retinas; throughMara Lorenzi 7
activity in endothelial and M¨ uller cells the pathway can be
a strong contributor to the disturbed ﬂuid homeostasis that
occurs in the diabetic retina and leads at times to macular
edema; through activity in endothelial cells and pericytes,
the pathway can be a strong contributor to the vascular cell
apoptosis that eventually results in acellular capillaries and
retinal ischemia. The preferred mechanism of cellular dam-
age by the polyol pathway appears to be the induction of ox-
idative stress, although other mechanisms should not be ig-
nored. Interventions with ARIs are successful when the doses
used reduce the ﬂux through the pathway and indices of ox-
idative stress.
In order to move forward and ascertain if what can hap-
pen does in fact happen, several needs must be met. The ﬁrst
is to have available new ARIs, best if more than one chemi-
cal type, combining higher levels of eﬃcacy, selectivity, and
safety in humans than those exhibited by older drugs. The
pharmaceutical industry may need to apply to the problem
some new thinking, especially in view of the fact that ARIs
could become the “one drug-option” for diabetic retinopa-
thy only if usable at doses that inhibit AR and ﬂux through
thepathwaymoresubstantiallythantheolderdrugs.Thesec-
ond need is clariﬁcation of whether distinct cell types in the
retina are exposed to speciﬁc consequences of, or have spe-
ciﬁc susceptibilities to, the diﬀerent mechanisms of cellular
damage initiated by the polyol pathway. Satisfying these two
needs may yield means with which to satisfy the third, which
is the identiﬁcation of reliable indicators of polyol pathway
activity.Indicatorsarenecessaryinordertolearnwhetherthe
polyol pathway is in fact active in the human diabetic retina,
and how best to inhibit the pathway with the new ARIs in
preparation for longer trials. In general, these needs are not
diﬀerentfromthose facedbyallothercandidate mechanisms
and drugs seeking a role in human diabetic retinopathy [84].
We all look forward to bringing one or more adjunct treat-
ment to clinical reality, and may ultimately welcome the re-
silience of the polyol pathway if we were to ﬁnd that it has
unique roles and/or it oﬀers unique solutions to human dia-
betic retinopathy.
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